Check out this September recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.
Commentary|Articles|March 24, 2026
Thoracic Oncologists Preview Most Anticipated Abstracts From ELCC 2026
Author(s)Caroline Seymour
Fact checked by: Kyle Doherty
Read on to see what abstracts experts in the field of lung cancer are interested in learning more about at ELCC 2026 in Copenhagen, Denmark.
Advertisement
Advertisement
Ahead of this year’s European Lung Cancer Congress (ELCC), which will be held from March 25 to 28 in Copenhagen, Denmark, OncLive® asked leading oncologists in the lung cancer space to share what presentations they are most excited to learn more about during the meeting and why.
Related to this article
The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
China's approval of Dato-DXd for TNBC was supported by TROPION-Breast02 data showing a median OS of 23.7 months vs 18.7 months with chemotherapy.
The NMPA approved T-DXd after neoadjuvant therapy, based on DESTINY-Breast05 data, in which the agent lowered the risk of recurrence or death vs T-DM1.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.
Advertisement
Advertisement